The estimated Net Worth of Christopher J. Senner is at least $24.8 Milion dollars as of 9 August 2024. Mr Senner owns over 125,000 units of Exelixis Inc stock worth over $22,547,088 and over the last 9 years he sold EXEL stock worth over $1,174,585. In addition, he makes $1,064,968 as Exec. VP & CFO at Exelixis Inc.
Mr has made over 12 trades of the Exelixis Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 125,000 units of EXEL stock worth $3,051,250 on 9 August 2024.
The largest trade he's ever made was exercising 225,000 units of Exelixis Inc stock on 11 August 2022 worth over $1,397,250. On average, Mr trades about 17,879 units every 55 days since 2015. As of 9 August 2024 he still owns at least 846,680 units of Exelixis Inc stock.
You can see the complete history of Mr Senner stock trades at the bottom of the page.
Christopher J. Senner is the Exec. VP & CFO at Exelixis Inc.
As the Exec. VP & CFO of Exelixis Inc, the total compensation of Mr Senner at Exelixis Inc is $1,064,968. There are 3 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
Mr Senner is 53, he's been the Exec. VP & CFO of Exelixis Inc since . There are 15 older and 6 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey a Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: